Kura Oncology Reports Positive Interim Data From Phase II Tipifarnib Trial for T-Cell Lymphoma

NEW YORK – Kura Oncology reported positive interim data from its ongoing Phase II trial of its lead drug candidate, tipifarnib, in the treatment of angioimmunoblastic T-cell lymphoma (AITL). The results from the trial were presented at the American Society of Hematology (ASH) Annual meeting in Orlando on Sunday.